Glycine Treatment of Prodromal Symptoms

Yale University

Status and phase: Completed; Phase 2

Conditions: Schizophrenia

Treatments: Drug: glycine

Study type: Interventional

Funder types: Other

Identifiers

NCT00268749

02T-175

Details and patient eligibility

About

This is an open label trial of the NMDA agonist glycine used alone for symptoms that appear to be prodromal for schizophrenia in adolescents and young adults.

Enrollment: 10 patients

Sex: All

Ages: 14 to 35 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• age 14-35
• meets SIPS criteria for psychosis prodrome

Exclusion criteria

• current antipsychotic medication
• more than 4 weeks of antipsychotic medication lifetime

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

10 participants in 1 patient group

1

Experimental group

Treatment:

Drug: glycine